MUTUAL CONFIDENTIALITY AGREEMENTMutual Confidentiality Agreement • September 5th, 2017 • Kite Pharma, Inc. • Biological products, (no disgnostic substances) • California
This Mutual Confidentiality Agreement (“Agreement”) is effective as of February 10, 2017 (“Effective Date”), between Kite Pharma, Inc., a Delaware corporation having a place of business at 2225 Colorado Avenue, Santa Monica, CA 90404 (“Kite”) and Gilead Sciences, Inc., a Delaware corporation having a place of business at 333 Lakeside Drive, Foster City, CA 94404 (“Company”). Kite and Company may be referred to herein individually as a “Party” and collectively as the “Parties.”
GILEAD SCIENCES, INC. AMENDMENT NO. 1 TO MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENTMutual Confidential Disclosure Agreement • September 5th, 2017 • Kite Pharma, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 (this “Amendment”) to the Mutual Confidential Disclosure Agreement dated February 10, 2017 (the “Original Agreement”) is made effective as of August 20, 2017 (“Amendment Effective Date”) by and between Gilead Sciences, Inc. (“Company”) and Kite Pharma, Inc. (“Kite”). Capitalized terms used and not otherwise defined herein shall have the meanings given such terms in the Original Agreement to the extent defined therein.
Kite Pharma, Inc.Kite Pharma, Inc. • September 5th, 2017 • Biological products, (no disgnostic substances)
As we previously announced, on August 27, 2017, Kite Pharma, Inc. (“Kite”) entered into a merger agreement providing for the acquisition of Kite by Gilead Sciences, Inc. (“Gilead”). In the acquisition, Kite stockholders will receive $180.00 for each share of Kite common stock that they hold.
